bioplasm

(redirected from Biogen)
Also found in: Dictionary, Wikipedia.

bi·o·plasm

(bī'ō-plazm),
Protoplasm, especially in its relation to living processes and development.
[bio- + G. plasma, thing formed]

bioplasm

A nonspecific term for germinal material within cells, which is regarded as essential to life functions—e.g., cytoplasm or protoplasm.

bioplasm

Mentioned in ?
References in periodicals archive ?
ZEVALIN radioimmunotherapy represents a major advancement in the treatment of certain non-Hodgkin's lymphomas," said Burt Adelman, executive vice president, Development for Biogen Idec.
Guidance for full-year 2003 reported earnings per share, which is the most comparable GAAP-based financial measure to operating earnings per share, is not currently accessible as Biogen cannot predict with any certainty the nature or the amount of non-operating or unusual charges for subsequent quarters.
To help disseminate information, Biogen hosted a teleconference to provide quick access to its medical experts for Society chapters, clinic administrators, and other members of the MS community nationwide.
News of the Biogen deal came as a regulatory filing disclosed that Icahn had increased his stake in video game publisher Take-Two Interactive Software Inc.
If the Court of Appeals were to rule against Biogen and return the case to the District Court, Biogen believes that decision likely would require it to make a second and final payment of $55 million to Berlex.
In December, Biogen settled its dispute with ASTA Medica (Frankfurt, Germany) relating to a terminated 1989 agreement among Biogen, ASTA and Bioferon under which ASTA had obtained a license to certain intellectual property rights related to recombinant beta interferon for a number of European countries.
We believe Biogen Idec is materially undervaluing our assets while overstating our liabilities, and their offer demonstrates an incomplete understanding of our pipeline and technologies," Hasnain said.
Biogen Launches Hostile $355 Million Bid for Facet.
Facet Biotech Rises after Board Rejects Biogen Takeover Bid.
Biogen Idec (NASDAQ: BIIB) today announced it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three individuals, Thomas F.
But Biogen will argue that while the contract may not have been breached in substance, it has been breached in form.
Investor Carl Icahn will nominate four directors to Biogen Idec Inc.